Skip to main content
AGTX
OTC Life Sciences

Agentix Q2: $1,312 Cash, $3.8M Working Capital Hole, Going Concern Intact

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.034
Mkt Cap
$1.35M
52W Low
$0.014
52W High
$0.46
52W Position info
137% above low
Off High info
93% below high
Rel. Volume
Market data snapshot near publication time

AGTX has more than doubled off its 52-week low of $0.014.

Summary

Agentix reported a $208,699 six-month net loss with just $1,312 of cash and a $3.8M working capital deficit, repeating going-concern doubt and relying on insider advances to stay afloat.


Key Events · Earnings and Guidance · AGTX

  • Going Concern Doubt Reiterated

    Management states cash is not sufficient to support daily operations and that absent financing 'our business will likely fail.'

  • Cash of $1,312 vs $3.8M Current Liabilities

    Cash was $1,312 against total current liabilities of $3,808,337, leaving a working capital deficit of $3,807,025 at September 30, 2026.

  • Six-Month Net Loss of $208,699

    Net cash used in operating activities was $29,894 for the six months ended September 30, 2026, funded partly by $33,250 of new debt proceeds.

  • Insider Advances Fund the Company

    Accounts payable to related parties reached $2,519,108, including $1,619,189 to SBS Management and $529,073 to Gray's Peak Capital, plus a $386,700 secured note at 2% per month.


Analysis · AGTX · Life Sciences

Agentix ended September 30, 2026 with $1,312 of cash against $3,808,337 of current liabilities — a $3,807,025 working capital deficit — and management repeats that without new financing 'our business will likely fail.' The six-month operating cash burn was only $29,894 because the company is barely operating, but insiders are bridging the gap: related-party payables rose to $2,519,108, including $1,619,189 owed to SBS Management and $529,073 to Gray's Peak Capital, plus a $386,700 secured note accruing 2% per month. Any equity raise at the current $0.0337 price would be massively dilutive given only 50,000,000 authorized shares versus 40,066,951 outstanding. The company also disclosed that disclosure controls and procedures were not effective and faces a $44,991 vendor debt-recovery claim in Australia.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AGTX was trading at $0.03 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.01 to $0.46. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AGTX - Latest Insights

AGTX
Jul 01, 2026, 6:05 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.020
Real-time Price: $0.0336 info
Change: Low Volume info
Market Cap: $1.346M info
AGTX
Jun 30, 2026, 7:36 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.020
Real-time Price: $0.0336 info
Change: Low Volume info
Market Cap: $1.346M info
AGTX
Feb 17, 2026, 1:26 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.04198
Real-time Price: $0.0336 info
Change: Low Volume info
Market Cap: $1.346M info